WASHINGTON, DC (February 20, 2020) — “America looks to new generic drugs for significant savings on medicine, but our newest data show Medicare and commercial health plans delay their coverage. Delayed competition from generics increases costs for patients, taxpayers and employers and rewards the makers of high-priced brand-name drugs.
Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27